Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-05-01
2007-05-01
Marschel, Ardin H. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S312000, C514S414000, C514S404000, C514S469000
Reexamination Certificate
active
11205474
ABSTRACT:
The present invention concerns compounds and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers characterized by over-activity or inappropriate activity c-kit kinase.
REFERENCES:
patent: 4376110 (1983-03-01), David et al.
patent: 4966849 (1990-10-01), Vallee et al.
patent: 5217999 (1993-06-01), Levitzki et al.
patent: 5330992 (1994-07-01), Eissenstat et al.
patent: 5792783 (1998-08-01), Tang et al.
patent: 5883116 (1999-03-01), Tang et al.
patent: 5905149 (1999-05-01), Battistini et al.
patent: 6339100 (2002-01-01), Longley
patent: 6395734 (2002-05-01), Tang et al.
patent: 6514981 (2003-02-01), Tang et al.
patent: 6689806 (2004-02-01), Tang et al.
patent: 6878733 (2005-04-01), Shenoy et al.
patent: WO 91/15495 (1991-10-01), None
patent: WO 92/20642 (1992-11-01), None
patent: WO 92/21660 (1992-12-01), None
patent: WO 94/03427 (1994-02-01), None
patent: WO 94/10202 (1994-05-01), None
patent: WO 94/14808 (1994-07-01), None
patent: WO 96/22976 (1996-08-01), None
patent: WO 98/07695 (1998-02-01), None
patent: WO 99/06468 (1999-02-01), None
patent: WO 99/10325 (1999-03-01), None
patent: WO 99/61422 (1999-12-01), None
Akbasak, A., “Oncogenes: Cause Or Consequence In The Development Of Glial Tumors,”Journal of the Neurological Sciences, 1992, 119-133, vol. 111.
Andoh, A., “Rapid Intestinal Ischaemia-Reperfusion Injury Is Suppressed In Genetically Mast Cell-Deficient Ws/Ws Rats,”Clinical Experimental Immunology, 1999, 90-93, vol. 116.
Beck, D., “Expression Of Stem Cell Factor And Its Receptor By Human Neuroblastoma Cells And Tumors,”Blood, 1995, 3132-3138, vol. 86, No. 8.
Bedi, A., “BCR-ABL-Mediated Inhibition Of Apoptosis With Delay Of G2/M Transition After DNA Damage: A Mechanism Of Resistance To Multiple Anticancer Agents,”Blood, 1995, 1148-1158, vol. 86, No. 3.
Bellone, G., “Growth Stimulation Of Colorectal Carcinoma Cells Via The c-Kit Receptor Is Inhibited By TGF-β1,”Journal of Cellular Physiology, 1997, 1-11, vol. 172.
Berdel, W., “Recombinant Human Stem Cell Factor Stimulates Growth Of A Human Glioblastoma Cell Line Expressing c-Kit Protooncogene,”Cancer Research, 1992, 3498-3502, vol. 52.
Blume-Jensen, P., “Kit/Stem Cell Factor Receptor-Induced Activation Of Phosphatidylinositol 3′-Kinase is Essential for Male Fertility,” Nature Genetics, 2000, 157-162, vol. 24.
Bokemeyer, C., “Expression Of Stem-Cell Factor And Its Receptor c-Kit Protein In Normal Testicular Tissue And Malignant Germ-Cell Tumours,” Journal of Cancer Research and Clinical Oncology, 1996, 301-306, vol. 122.
Broudy, V., “Stem Cell Factor and Hematopoiesis,”Blood, 1997, 1345-1364, vol. 90, No. 4.
Carpino, N., “p62dok:A Constitutively Tyrosine-Phosphorylated, GAP-Associated Protein In Chronic Myelogenous Leukemia Progenitor Cells,”Cell, 1997, 197-204, vol. 88.
Castells, M., “The Presence Of Membrane-Bound Stem Cell Factor On Highly Immagture Nonmetachromatic Mast Cells In The Peripheral Blood Of A Patient With Aggressive Systemic Mastocytosis,”Journal of Allergy and Clinical Immunology, 1996, 831-840, vol. 98, No. 4.
Chao, M., “Growth Factor Signaling: Where Is The Specificity?” Cell, 1992, 995-997, vol. 68.
Cohen, P., “Expression Of Stem Cell Factor And c-Kit In Human Neuroblastoma,”Blood, 1994, 3465-3472, vol. 84, No. 10.
Columbo, M., “The Human Recombinant c-Kit Receptor Ligand, rhSCF, Induces Mediator Release From Human Cutaneous Mast Cells And Enhances IgE-Dependent Mediator Release From Both Skin Mast Cells And Peripheral Blood Basophils,”The Journal of Immunology, 1992, 599-608, vol. 149, No. 2.
Costa, J., “The Cells Of The Allergic Response,”JAMA, 1997, 1815-1822, vol. 278, No. 22.
Dastych, J., “Stem Cell Factor Induces Mast Cell Adhesion To Fibronectin,” Journal of Immunology, 1994, 213-219, vol. 152.
Dickson, R., “Tyrosine Kinase Receptor—Nuclear Protooncogene Interactions In Breast Cancer,”Genes, Oncogenes, and Hormones: Advances In Cellular And Molecular Biology of Breast Cancer, 1991, 249-273, Kluwer Academic Publishers, Boston.
Driancourt, M., “Roles Of Kit and Kit Ligand In Ovarian Function,”Reviews of Reproduction, 2000, 143-152, vol. 5.
Dyson, N., “The Human Papilloma Virus—16 E7 Oncoprotein Is Able To Bind To The Retinoblastoma Gene Product,”Science, 1989, 934-937, vol. 243.
Escribano, L., “Expression of the C-Kit (CD117) Molecule In Normal And Malignant Hematopoiesis,”Leukemia and Lymphoma, 1998, 459-466, vol. 30.
Feng, H., “Decreased Expression Of The C-Kit Receptor Is Associated With Increased Apoptosis In Subfertile Human Testes,”Fertility and Sterility, 1999, 85-89, vol. 71, No. 1.
Finotto, S., “Glucocorticoids Decrease Tissue Mast Cell Number By Reducing The Production Of the C-Kit Ligand, Stem cell Factor, By Resident Cells,”The Journal of Clinical Investigation, 1997, 1721-1728, vol. 99, No. 7.
Furitsu, T., “Identification Of Mutations In The Code Sequence Of The Prot-Oncogene C-Kit in A Human Mast Cell Leukemia Cell Line Causing Ligand-Independent Activiation of C-Kit Product,”Journal of Clinical Investigation, 1993, 1736-1744, vol. 92.
Furuta, G., “Stem Cell Factor Influences Mast Cell Mediator Release In Response To Eosinophil-Derived Granule Major Basic Protein,”Blood, 1998, 1055-1061, vol. 92, No. 3.
Gaca, M., “Human And Rat Hepatic Stellate Cells Produce Stem Cell Factor: A Possible Mechanism For Mast Cell Recruitment In Liver Fibrosis,”Journal of Hepatology, 1999, 850-858, vol. 30.
Golkar, L., “Mastocytosis,”Lancet, 1997, 1379-1385, vol. 349.
Hallek, M., “Interaction Of The Receptor Tyrosine Kinase p145c-kitWith the p210bcr/ablKinase In Myeloid Cells,”British Jounral of Haematology, 1996, 5-16, vol. 94.
Hamel, W., “The Road Less Travelled: C-Kit And Stem Cell Factor,”Journal of Neuro-Oncology, 1997, 327-333, vol. 35.
Hassan, H.T., “Stem Cell Factor As A Survival And Growth Factor In Human Normal And Malignant Hematopoiesis,”Acta Haematology, 1996, 257-262, vol. 95.
Hibi, K., “Coexpression Of The Stem Cell Factor And The C-Kit Genes In Small-Cell Lung Cancer,”Oncogene, 1991, 2291-2296, vol. 6.
Hirota, S., “Gain-Of-Function Mutations Of C-Kit In Human Gastrointestinal Stromal Tumors,”Science, 1998, 577-580, vol. 279.
Holgate, S., “Asthma: A Dynamic Disease Of Inflammation And Repair,”Ciba Foundation Symposium, 1997, 5-34, vol. 206.
Iemura, A., “The C-Kit Ligand, Stem Cell Factor, Promotes Mast Cell Survival By Suppressing Apoptosis,”American Journal Of Pathology, 1994, 321-328, vol. 144, No. 2.
Inoue, M. “Coexpression Of The C-Kit Receptor And The Stem Cell Factor In Gynecological Tumors,”Cancer Research, 1994, 3049-3053, vol. 54.
Isozaki, K., “Deficiency Of C-Kit+ Cells In Patients With A Myopathic Form Of Chronic Idiopathic Intestinal Pseudo-Obstruction,”The American Journal of Gastroenterology, 1997, 332-334, vol. 92, No. 2.
Izquierdo, M., “Differential Expression Of The C-Kit Proto-Oncogene In Germ Cell Tumours,”Journal of Pathology, 1995, 253-258, vol. 177.
Jellinek, D., “Inhibition Of Receptor Binding By High-Affinity RNA Ligands To Vascular Endothelial Growth Factor,”Biochemistry, 1994, 10450-10456, vol. 33.
Jones, R., “Biology And Treatment Of Chronic Myeloid Leukemia,”Current Opinion in Oncology, 1997, 3-7, vol. 9.
Kendall, R., “Inhibition Of Vascular Endothelial Cell Growth Factor Activity By An Endogenously Encoded Soluble Receptor,”PNAS USA, 1993, 10705-10709, vol. 90.
Kim, K., “Inhibition Of Vascular Endothelial Growth Factor-Induced Angiogenesis Suppresses Tumour Growth In Vivo,”Nature, 1993, 8
Lipson Ken
McMahon Gerald
Gembeh Shirley V.
Liptak Vincent P.
Marschel Ardin H.
Sugen Inc.
Zielinski Bryan C.
LandOfFree
Methods of modulating c-kit tyrosine protein kinase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of modulating c-kit tyrosine protein kinase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of modulating c-kit tyrosine protein kinase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3735138